The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Reducing gastrointestinal adverse events in patients receiving immunotherapy
Yinghong Wang, MD, PhD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the impact of immunotherapy-related adverse events on treatment outcomes in patients with gastrointestinal cancers. The severity of certain side effects may result in the interruption of treatment, which negatively impacts survival in patients. There is consequently a need for safe, efficacious treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
